Home » Newsletters » BioWorld Science

BioWorld Science

April 10, 2000

View Archived Issues

Hybridon presents preclinical results with MDM2 antisense compound at AACR

ImClone Systems reports positive preclinical data from gp75 melanoma vaccine study

Celtrix receives U.S. patent for use of SomatoKine as diabetes therapy

Intranasal morphine pilot clinical trial results reported

Obesity drug slated to enter phase I trials next month

Alizyme's phase IIa trial of renzapride is fully enrolled

Hepatitis B vaccine incorporating new adjuvant requires fewer doses, has enhanced efficacy

NeoTherapeutics completes enrollment in phase IIb Neotrofin trial and initiates open-label extension

Progenics reports HIV therapy progress at Keystone symposium

Gilead licenses NX-1838, a new AMD treatment, to EyeTech

Janssen to discontinue development of R-121919 and substitute with a backup compound

Formamide compounds from Glaxo Wellcome inhibit TNF-alpha release and MMP activity

Scotia and Techniclone sign letter of intent related to licensing of VTA

New class of matrix metalloproteinase inhibitors in development by AstraZeneca

Abbott designs macrolide LHRH antagonists

Dendreon describes preparation and use of apoptosis-inducing HLA-DR-specific MAbs

Immune Network Research and Bridge Pharma expand joint venture

Novel serotonergic compounds from Cerebrus particularly useful for obesity Rx

BMS synthesizes new potassium channel blockers for cardiac arrhythmias

SkyePharma and Amgen sign development contract

Small-molecule chemokine receptor antagonists jointly developed by LeukoSite and Kyowa Hakko

Psoriatic arthritis patients sought for clinical trial

Sultams prove to be potent NNRTIs in biological screens; work presented at ACS meeting

Cogent Neuroscience secures funds to accelerate neuroprotective gene discovery program

TBC-3342: a potent urea VLA-4 antagonist designed at Texas Biotechnology

Wyeth Lederle Vaccines gains expanded access to Corixa's MPL adjuvant

Cannabinoid receptor affinity probes designed by U. of Connecticut scientists

Highly potent, non-thiol-containing FTase inhibitor characterized by BMS at AACR meeting

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...